PMID- 20386557
OWN - NLM
STAT- MEDLINE
DCOM- 20110614
LR  - 20181201
IS  - 1440-1711 (Electronic)
IS  - 0818-9641 (Linking)
VI  - 88
IP  - 8
DP  - 2010 Nov-Dec
TI  - Immunosuppressive properties of human umbilical cord-derived mesenchymal stem 
      cells: role of B7-H1 and IDO.
PG  - 795-806
LID - 10.1038/icb.2010.47 [doi]
AB  - Umbilical cord is a rich source of mesenchymal stromal or stem cells (MSCs) that 
      can be used for developing allogeneic cell therapy to treat intractable diseases. 
      In this report, we present evidence that umbilical cord-derived MSCs (UCMSCs) 
      possess important immunomodulatory properties that may enable them to survive in 
      an allogeneic environment. UCMSCs do not express human leukocyte antigen (HLA)-DR 
      and co-stimulatory molecules CD80 and CD86 that are required for T-cell 
      activation. More importantly, UCMSCs constitutively express a negative regulator 
      of T-cell activation, B7-H1, and its expression is increased after interferon-gamma 
      (IFN-gamma) treatment. In addition, IFN-gamma treatment induced indoleamine 
      2,3-dioxygenase (IDO) and HLA-DR expression in UCMSCs. Neither control nor 
      IFN-gamma-treated UCMSCs stimulated allogeneic T-cell proliferation, and both cell 
      populations inhibited third-party dendritic cell (DC)-mediated allostimulatory 
      activity. Addition of a B7-H1-specific blocking antibody or an IDO inhibitor, 1 
      methyl tryptophan (1-MT) abrogated the T-cell immunosuppressive activity of these 
      cells. Furthermore, UCMSCs prevented the differentiation and maturation of 
      peripheral blood monocyte-derived DCs, and augmented the generation of regulatory 
      T cells (Tregs) in culture. The immunosuppressive effects of UCMSCs are largely 
      mediated by cell-to-cell contact, although some inhibitory activity was observed 
      with cell-free supernatant. Our study suggests that these immunomodulatory 
      properties of UCMSCs could potentially improve the outcome of allogeneic stem 
      cell therapy.
FAU - Tipnis, Shabari
AU  - Tipnis S
AD  - Regenerative Medicine, Reliance Life Sciences Pvt Ltd, Dhirubhai Ambani Life 
      Sciences Centre, Navi Mumbai, Maharashtra, India.
FAU - Viswanathan, Chandra
AU  - Viswanathan C
FAU - Majumdar, Anish S
AU  - Majumdar AS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100413
PL  - United States
TA  - Immunol Cell Biol
JT  - Immunology and cell biology
JID - 8706300
RN  - 0 (Antibodies, Blocking)
RN  - 0 (Antigens, CD)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (CD274 protein, human)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Indoleamine-Pyrrole 2,3,-Dioxygenase)
RN  - 82115-62-6 (Interferon-gamma)
RN  - 8DUH1N11BX (Tryptophan)
SB  - IM
MH  - Antibodies, Blocking/pharmacology
MH  - Antigens, CD/immunology/*metabolism
MH  - B7-H1 Antigen
MH  - Cell Communication/immunology
MH  - Cell Differentiation/drug effects
MH  - Cell Proliferation/drug effects
MH  - Cells, Cultured
MH  - Dendritic Cells/metabolism/pathology
MH  - Fetal Blood/cytology
MH  - HLA-DR Antigens/genetics/metabolism
MH  - Humans
MH  - Immune Tolerance/drug effects
MH  - Indoleamine-Pyrrole 2,3,-Dioxygenase/genetics/*metabolism
MH  - Interferon-gamma/immunology/metabolism
MH  - Lymphocyte Activation
MH  - Lymphocyte Culture Test, Mixed
MH  - Mesenchymal Stem Cells/cytology/drug effects/immunology/*metabolism
MH  - T-Lymphocytes, Regulatory/metabolism/pathology
MH  - Tryptophan/analogs & derivatives/pharmacology
EDAT- 2010/04/14 06:00
MHDA- 2011/06/15 06:00
CRDT- 2010/04/14 06:00
PHST- 2010/04/14 06:00 [entrez]
PHST- 2010/04/14 06:00 [pubmed]
PHST- 2011/06/15 06:00 [medline]
AID - icb201047 [pii]
AID - 10.1038/icb.2010.47 [doi]
PST - ppublish
SO  - Immunol Cell Biol. 2010 Nov-Dec;88(8):795-806. doi: 10.1038/icb.2010.47. Epub 
      2010 Apr 13.